Introduction : This study aims to investigate the relationship between IL-4 expression with Apoptosis-associated gene receptors (PD-1, CTLA-4) and Programmed Death-1 Ligands (PD-L1, PD-L2) in the microenvironment of prostate cancer tissue.Methods : The samples were collected from single-center hospital in a period from 2014 to 2020. Deparaffinize formalin-fixed paraffin-embedded and RNAs extraction by manufacturer’s protocol with slight modification was performed. The RNAs expressions were investigated by using quantitative real-time polymerase chain reaction. Then we categorize them into 4 groups. The ANOVA test is used to compare mean expression between groups and followed by a correlation test using Pearson test.Result : In the BPH group sample, CTLA-4 had the highest expression level, followed by the expression of IL-4, PD-L2, then PD-1 and PD-L1. The concentration of IL-4 in prostate cancer, both metastatic and non-metastatic, is higher than in BPH, with a p-value of 0.006. the correlation between IL-4 and PD-L1 is the strongest (r=0.919), between IL-4 and PD-L2 comes the second (0.832) and between PD-1 is comes the third (r=0.626).Conclusion : In this study, we find that the expression of IL-4 and Apoptosis-Associated Gene Receptors (PD-1, CTLA-4) and Programmed Death-1 Ligands (PD-L1, PD-L2) in the prostate cancer tissue microenvironment have a significant relationship. In conclusion, it is possible that IL-4 is a promoter of the Immune Escape mechanism in prostate cancer.

Prostate cancer is the fourth most common type of non-skin malignancy in male malignancies. In Indonesia, the definitive data are unreported, however, Globocan reported prostate cancer in 5 th place in 2018. The aim of this study is to provide in updating database of prostate cancer profile in tertiary hospital in Indonesia. A retrospective study involving a total of 90 prostate cancer patients who underwent follow-up care at Dr. Sardjito General Hospital, Yogyakarta in the period of 2015 to 2020 was conducted. Data of the patients from their medical records consisted of age, gender, prostate volume, PSA level, testosterone level, hydronephrosis, TURP history. From a total 90 subjects, showed an average age of 67 years (SD=10.4). The level of prostate volume (TAUS), most subjects were >30 cm3 with 73 subjects (81.4%). Of the total subjets, the median of total PSA value for diagnosis is 234.4 (94.4 -1720.3) ng/mL with the median of total testosterone value at diagnosis is 317 (10 -384) ng/dL. An equal between biopsy and TURP were used in method of diagnosis and histologic finding consisting of Adenocarcinoma were found in 88 subjects (97.8%) with Gleason score > 7 in 69 subject (69.6%) and ISUP Grade 5 in 59 subject (65.6%). The staging T1c was found in 43 subjects (47.8%) and M staging with metastasis stage was found in 55 subjects (61.1%). In conclusion, most patients with prostate cancer are identified as adenocarcinoma with metastatic stage. In general, the prostate cancer patients age more than 61 years old with prostate volume (TAUS) > 30 cm 3 . In addition, prostate volume and testosterone level can be routinely used as initial screening and periodic assessment to evaluate prognosis and disease progression.